Two Cases of *Borrelia miyamotoi* Meningitis, Sweden, 2018

Anna J. Henningsson, Hilmir Asgeirsson, Berit Hammas, Elias Karlsson, Åsa Parke, Dieuwertje Hoornstra, Peter Wilhelmsson, Joppe W. Hovius

We report 2 human cases of *Borrelia miyamotoi* disease diagnosed in Sweden, including 1 case of meningitis in an apparently immunocompetent patient. The diagnoses were confirmed by 3 different independent PCR assays and DNA sequencing from cerebrospinal fluid, supplemented by serologic analyses.

*Borrelia miyamotoi* is the cause of an emerging disease in the Northern Hemisphere, transmitted by hard (Ixodes) ticks. The bacterial species, described in Japan in 1995 (1), is genetically related to the relapsing fever borreliae and may be divided into Siberian, European, and American genotypes (2). *B. miyamotoi* disease (BMD), described in case series from Russia (3) and the United States (4–5), is a systemic illness causing relapsing fever, headache, myalgia, arthralgia, elevated liver enzymes, neutropenia, and thrombocytopenia. In addition, 3 cases of meningoencephalitis caused by *B. miyamotoi* have been reported worldwide, 2 from Europe and 1 from the United States, all in highly immunocompromised patients (6–8). We report 2 human cases of BMD diagnosed in Sweden, including 1 case of meningitis in an apparently immunocompetent patient.

The Patients

On July 29, 2018, a 53-year-old woman (patient A) sought care at a hospital for headache, neck stiffness, and high-grade fever that had progressively worsened during the preceding week (Figure 1, panel A). Her medical history included previous cholecystectomy and gastric bypass surgery. Her sole medication was oxycodone (an opioid drug used to manage pain), which she was taking because of a recent elbow fracture. She had not been abroad during the preceding months but she had removed an attached tick while staying in Stockholm County 6 weeks earlier. No subsequent erythema appeared around the bite site. At admission, we found no neurologic deficits or signs of impaired consciousness. Cerebrospinal fluid (CSF) analysis showed total leukocyte count 321 cells/µL (reference ≤5 cells/µL), mononuclear cells 276 cells/µL (reference ≤5 cells/µL), and albumin 1,270 mg/L (reference <420 mg/L). Bacterial culture; anti-*Borrelia* antibody testing; and PCR for herpes simplex virus, varicella zoster virus, and enterovirus were negative in CSF. Serologic test results for tickborne encephalitis were negative. Viral meningitis was suspected.

The next day, clinical improvement occurred, and the patient was discharged. However, the patient’s condition then worsened, with more pronounced headache and neck pain, and she was readmitted on August 6. Blood cell and platelet counts and C-reactive protein levels were normal. CSF analysis showed total leukocyte count 517 cells/µL (reference ≤5 cells/µL), mononuclear cells 354 cells/µL (reference ≤5 cells/µL), and albumin 1,270 mg/L (reference <420 mg/L). *B. miyamotoi* rRNA gene sequencing (9) of the CSF sample suggested *B. miyamotoi*, a finding that later was confirmed by specific PCR, sequencing, and serologic testing (Table).

At follow-up on August 24, the patient showed continued improvement without any fever relapses. Complementary tests for immunodeficiency showed normal serum levels of immunoglobulins. We analyzed convalescent serum using several commercially available tests for laboratory diagnosis of Lyme borreliosis (Table); all results were negative.

A 66-year-old woman (patient B) living in Stockholm County was referred in August 2018 for 6 weeks of intermittent high-grade fever and 9 months of various other symptoms (Figure 1, panel B). She had rheumatoid arthritis, treated with methotrexate together with rituximab twice a year since 2011, but had been physically very active. Her symptoms began with headache and increasing fatigue in November 2017, a few days after returning from a 2-week
trip to California and Nevada, USA. She had not noticed any tick bites during the trip but had had several tick bites in Sweden during the summer of 2017. She subsequently started experiencing progressing difficulties with concentration and memory and had relapsing febrile episodes. In January 2018, she received diagnoses of uveitis and iritis; vitritis of unknown cause was later diagnosed. She also had progressive hearing loss, and hearing aids were prescribed. In addition, she had loss of appetite and weight (15 kg within 6 months). In May she had a short episode of left-sided weakness, and transient ischemic attack was suspected. All this resulted in her quitting her work as an accountant and hardly being able to leave her house.

Upon referral, we performed a lumbar puncture, which showed total CSF leukocytes of 331 cells/µL (reference <5 cells/µL), 273 cells/µL mononuclear (reference <5 cells/µL). Table. Confirmatory analyses performed on cerebrospinal fluid and serum/plasma samples from 2 patients with diagnoses of meningitis caused by *Borrelia miyamotoi*, Sweden, 2018*

| Analysis                  | Jul 30  | Aug 6   | Aug 24  | Aug 9   | Oct 31  |
|---------------------------|---------|---------|---------|---------|---------|
| BM-specific PCR           | Serum   | +       |         | NA      | NA      |
| BM-specific PCR           | CSF     | –       |         | NA      | NA      |
| BM-specific serologic testing | IgM+ (GlpQ, Vlp5), IgG– | NA | IgM+ (GlpQ, Vlp5), IgG+ (GlpQ) | NA | IgM+ (GlpQ, Vlp5), IgG+ (GlpQ) |
| BM-specific serologic testing | IgM+ (GlpQ, Vlp5), IgG– | NA | NA      | IgM+ (GlpQ, Vlp5), IgG+ (GlpQ) |
| LB serology†              | –       | –       | –       | IgM AI+ | –      |
| Culture attempts          | –       | –       | –       | NA      | NA      |

*Patient A: a 53-year-old immunocompetent woman; patient B: a 66-year-old immunocompromised woman; AI, antibody index; BM, *Borrelia miyamotoi*; CSF, cerebrospinal fluid; GlpQ, glycerophosphodiester-phosphodiesterase; LB, Lyme borreliosis; NA, not analyzed; Vlp, variable large protein; Vsp, variable small protein; +, positive; −, negative.

†LIAISON *Borrelia burgdorferi* (DiaSorin, https://www.diasorin.com).

‡In addition to LIAISON, the sample was analyzed by Enzygnost Lyme link VlsE: IgG and Enzygnost Borrelia IgM (DADE Behring, https://www.siemens.com), recomBead Borrelia IgM and IgG (Mikrogen GmbH, https://www.mikrogen.de), C6 Lyme ELISA Kit (Immunetics, https://immunetics.com) and Anti-Borrelia EUROLINE-RN-AT IgG and IgM (EUROIMMUN, http://www.euroimmun.com). All test results were negative.
Borrelia miyamotoi Meningitis, Sweden

µL), albumin 1,550 mg/L (reference <420 mg/L), lactate 4.2 mmol/L (reference 1.2–2.1 mmol/L), and CXCL13 >500 pg/mL (reference <250 pg/mL). Magnetic resonance imaging showed contrast enhancement in both oculomotor nerves and the left trigeminal nerve, as well as thickening of the pituitary stalk. CSF was PCR negative for herpes simplex virus, varicella zoster virus, enterovirus, *Mycoplasma*, and *Toxoplasma*. Bacterial, mycobacterial, and fungal CSF cultures were negative. Serologic results for tickborne encephalitis and Lyme borreliosis were negative, with the exception of detectable *B. burgdorferi* IgM in CSF (Table). The 16S rRNA gene sequencing (9) was positive for *B. miyamotoi*.

We treated the patient with doxycycline (200 mg 2×/d for 14 d); within 5 days, the patient regained her hearing, and the fever and headache disappeared. MRI 1 month later showed an almost complete regression of the contrast enhancement of the cranial nerves. By follow-up 2 months after finishing the treatment, the patient had resumed employment and felt almost completely recovered.

We performed *B. miyamotoi* quantitative PCR (qPCR) targeting the flagellin gene, slightly modified from Hovius et al. (6) (Appendix, http://wwwnc.cdc.gov/EID/article/25/10/19-0416-App1.pdf). The 2 successive CSF samples and 1 serum sample from patient A were positive by qPCR, as were the CSF and plasma samples from patient B (Table).

From 1 of the CSF samples from patient A and the CSF sample from patient B, we confirmed the presence of *B. miyamotoi* by nested PCR amplification and sequencing of the glycerophosphodiester-phosphodiesterase (*glpQ*) and *p66* genes (6), as well as a fragment of the intergenic spacer (IGS) between the 16S rRNA and 23S rRNA genes (10) (Appendix). The DNA sequences of the 16S-23S IGS (Figure 2), *glpQ*, and *p66* from patients A and B were identical to *B. miyamotoi* sequences derived from Europe but different from sequences derived from Asia and North America, indicating BMD contracted in Europe.

We tested for GlpQ and variable major proteins (Vmps) IgM and IgG by ELISA, as described previously (11,12) (Table). A clear seroconversion from IgM to IgG against GlpQ was demonstrated in patient A, whereas patient B merely demonstrated IgM reactivity against GlpQ. However, in patient A, but not in patient B (the immunosuppressed patient), we could demonstrate IgM and IgG against different Vmps over time.

Finally, we pursued culture attempts in MKP-F media on CSF and serum samples drawn before initiation of
antimicrobial drug treatment, retrieved from −80°C (Table), as described by Koetsveld et al. (13). After 2 months of culture, all samples remained negative.

Conclusions
Epidemiologic surveillance of emerging tickborne pathogens is crucial to increase awareness of the diseases that can be contracted after tick bites. Previous studies have shown that B. miyamotoi is present in Ixodes ricinus ticks in Scandinavia (14,15), but no human cases of BMD have been reported, and public health importance has been uncertain. Until now, severe disease, including slowly progressive CNS symptoms (6,7), has been reported in immunocompromised patients, but our findings indicate that B. miyamotoi may also cause CNS infection in immunocompetent persons (patient A). The clinical presentation differs from that of LNB, and results of serologic tests that are routinely used for LNB diagnosis can be negative. Therefore, we need to raise awareness of BMD among healthcare providers and ensure that adequate diagnostic methods are available. BMD should be a differential diagnosis in cases of fever and CNS symptoms after a tick bite in both immunosuppressed and immunocompetent persons.

Acknowledgments
We thank the patients for giving us their permission to report about their clinical symptoms and disease course. We also thank Gärda Andersson for laboratory support.

Confirmatory tests were performed at the laboratory for Clinical Microbiology, Division of Laboratory Medicine, Region Jönköping County, Sweden (molecular analyses), and Center for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, the Netherlands (serological analyses and propagation attempts).

A.J.H. and P.W. were supported by the EU Interreg V program as part of the project ScAndTick Innovation (project ID 20200422, reference no. 2015-000167), and D.H. and J.W.H. were supported by ZonMW as part of the project “Ticking on Pandora’s Box, a study into tick-borne pathogens in Europe” (project no. 50-52200-98-313).

About the Author
Dr. Henningsson is a specialist in infectious diseases and clinical microbiology with a position as senior consultant in Region Jönköping County and as associate professor at Linköping University. Her primary research interest is tickborne diseases.

References
1. Fukunaga M, Takahashi Y, Tsuruta Y, Matsushita O, Ralph D, McClelland M, et al. Genetic and phenotypic analysis of Borrelia miyamotoi sp. nov., isolated from the ixodid tick Ixodes persulcatus, the vector for Lyme disease in Japan. Int J Syst Bacteriol. 1995;45:804–10. https://doi.org/10.1099/00207713-45-4-804
2. Talagrand-Reboul E, Boyer PH, Bergström S, Vial L, Boulanger N. Relapsing fevers: neglected tick-borne diseases. Front Cell Infect Microbiol. 2018;8:98. https://doi.org/10.3389/fcimb.2018.00098
3. Platonov A, Karan LS, Kolyasnikova NM, Makheeva NA, Toporkova MG, Maleev VV, et al. Humans infected with relapsing fever spirochaete Borrelia miyamotoi, Russia. Emerg Infect Dis. 2011;17:1816–23. https://doi.org/10.3201/eid1710.101474
4. Krause PJ, Narasimhan S, Wormser GP, Rollend L, Fikrig E, Lepore T, et al. Human Borrelia miyamotoi infection in the United States. N Engl J Med. 2013;368:291–3. https://doi.org/10.1056/NEJMc1215469
5. Molloy PJ, Telford SR III, Chowdri R, Lepore TJ, Gugliotta JL, Weeks KE, et al. Borrelia miyamotoi disease in the northeastern United States: a case series. Ann Intern Med. 2015;163:91–8. https://doi.org/10.7326/M15-0333
6. Hovijs JW, de Wever B, Sohne M, Brouwer MC, Coumou J, Wagemakers A, et al. A case of meningoencephalitis by the relapsing fever spirochaete Borrelia miyamotoi in Europe. Lancet. 2013;382:658. https://doi.org/10.1016/S0140-6736(13)61464-X
7. Gugliotta JL, Goethert HK, Berardi VP, Telford SR III. Meningoencephalitis from Borrelia miyamotoi in an immunocompromised patient. N Engl J Med. 2013;368:240–5. https://doi.org/10.1056/NEJMoa13109039
8. Boden K, Lobenstein S, Hermann B, Margus G, Fingerle V. Borrelia miyamotoi-associated neuroborreliosis in immunocompromised person. Emerg Infect Dis. 2016;22:1617–20. https://doi.org/10.3201/eid2209.152034
9. Beser J, Hallström BM, Advani A, Andersson S, Östlund G, Winecka-Krusnell J, et al. Improved the genotyping resolution of Cryptosporidium hominis subtype IaB10G2 using one step PCR-based amplicon sequencing. Infect Genet Evol. 2017;55:297–304. https://doi.org/10.1016/j.meegid.2017.08.035
10. Bunikis J, Garmpo U, Tao S, Berglund J, Fish D, Barbour AG. Sequence typing reveals extensive strain diversity of the Lyme borreliosis agents Borrelia burgdorferi in North America and Borrelia afzelii in Europe. Microbiology. 2004;150:1741–55. https://doi.org/10.1099/mic.0.26944-0
11. Wagemakers A, Koetsveld J, Narasimhan S, Wickel M, Deponte K, Bleijlevens B, et al. Variable major proteins as targets for specific antibodies against Borrelia miyamotoi. J Immunol. 2016;196:4185–95. https://doi.org/10.4049/jimmunol.1600014
12. Koetsveld J, Kolyasnikova NM, Wagemakers A, Stukolova OA, Hoornstra D, Sarksyan DS, et al. Serodiagnosis of Borrelia miyamotoi disease by measuring antibodies against GlpQ and variable major proteins. Clin Microbiol Infect. 2018;24:1338.e1–7. https://doi.org/10.1016/j.cmi.2018.03.009
13. Koetsveld J, Kolyasnikova NM, Wagemakers A, Toporkova MG, Sarksyan DS, Oei A, et al. Development and optimization of an in vitro cultivation protocol allows for isolation of Borrelia miyamotoi from patients with hard tick-borne relapsing fever. Clin Microbiol Infect. 2017;23:480–4. https://doi.org/10.1016/j.cmi.2017.08.035
14. Wilhelmsson P, Fryland L, Börjesson S, Nordgren J, Bergström S, Ermundt J, et al. Prevalence and diversity of Borrelia species in ticks that have bitten humans in Sweden. J Clin Microbiol. 2010;48:4169–76. https://doi.org/10.1128/JCM.01061-10
15. Kjelland V, Rollum R, Korslund L, Slettan A, Tveitnes D. Borrelia miyamotoi is widespread in Ixodes ricinus ticks in southern Norway. Ticks Tick Borne Dis. 2015;6:516–21. https://doi.org/10.1016/j.ttbdis.2015.04.004

Address for correspondence: Anna J. Henningsson, Region Jönköping County Clinical Microbiology, Sjukhusgatan 1 County Hospital Ryhov, Jönköping 55466, Sweden; email: anna.jonsson.henningsson@rjl.se